DuPont de Nemours, Inc.

NYSE: DD·Wilmington, Delaware·

Price
$149.99
Base IV
$85.12

Valuation snapshot

Above bull case

At $149.99, the price is above even our bull case of $121.26.

Values per share, from an .

No growth
…
Loading earnings power
Base case
$85.12
57% of the price · range $45.80–$121.26
Price vs base case
76% above
$149.99 against $85.12
Base casevalued by DCF
Price vs base
Priceclose 11‑16

Whisker on the base case runs bear $45.80 to bull $121.26. Values per share.

Price against each value

Bear case
$45.80
Price 227% above
No growth
…
—
Base case
$85.12
Price 76% above
Researched bygemini-3.8-flash-medium
Valuation Nov 5, 2026 · Price as of Nov 16, 2026How we got here

What does DuPont de Nemours do?

DuPont de Nemours provides medical packaging, components, and water filtration technologies to help healthcare and industrial customers manage water purification and medical device safety.

It brought in $7.1B of sales in the 12 months to Sep 2026.

Led by Lori D. Koch, Chief Executive Officer since 2024. DuPont de Nemours, Inc. Current Report on Form 8-K

DuPont Tyvek HomeWrap installed on a house under constructionImage: DuPont de Nemours
Industry
Materials
Based in
Wilmington, Delaware
Trades on
NYSE as DD

Here is where each dollar a customer pays ends up. Out of every $1 of sales in the 12 months to Sep 2026, about 4¢ was left as profit after every cost, interest and tax. The biggest cost is making what it sells, 65¢ of every dollar.

  • Making what it sells65¢
  • Research and development2¢
  • Sales, marketing and admin15¢
  • Everything else, including interest9¢
  • Tax4¢
  • Other items after tax1¢
  • Left as profit4¢
Totals of the four quarters to Sep 2026, from the company's own filings. The split by product is from the latest fiscal year.

Who pays DuPont de Nemours, and for what?

DuPont sells specialized materials, components and systems used in medical devices and packaging, water treatment, construction and industrial applications. It makes money by selling these products and related solutions to businesses around the world.

Its customers are businesses in healthcare, water treatment, construction, aerospace, automotive, printing and other industrial markets.

  • Healthcare & Water Technologies

    47%

    Medical packaging, medical device components, protective garments, and water filtration and purification products and systems.

    DuPont Tyvek sterile medical device packaging pouchImage: DuPont de Nemours
  • Diversified Industrials

    53%

    Building products such as house wrap and insulation, plus engineered components, adhesives, lubricants and printing plates for industrial customers. Revenue is total 2025 sales less Healthcare & Water Technologies sales.

    DuPont Tyvek HomeWrap installed on a house under constructionImage: DuPont de Nemours
Share of the latest fiscal year's sales, as the company reports it.

Where its work physically happens, beyond headquarters:

  • Edina FilmTec plant — Edina, United States. The Edina plant is a core production site for FilmTec reverse osmosis elements used in water purification and reuse.
  • Spruance Tyvek plant — Richmond, United States. Spruance produces Tyvek for healthcare packaging and other protective and industrial applications.
  • Luxembourg Tyvek plant — Luxembourg, Luxembourg. The Luxembourg plant supplies Tyvek and, alongside Richmond, supports DuPont’s certified renewable-attribution product range.
  • Global Water Technology Center — Tarragona, Spain. This industrial-scale research center tests water technologies and supports product launches and customer projects for DuPont Water Solutions.
  • Jubail FilmTec plant — Jubail, Saudi Arabia. Jubail is one of DuPont’s established FilmTec reverse osmosis manufacturing locations, supporting regional supply of water-treatment elements.
See them on the globe

DuPont 2025 Form 10-K

How is the business doing?

Sales shrank from $38.5B in 2018 to $6.8B in 2025, about 22% a year.

After paying for its upkeep and new investment, it had $793M of cash to spare in the 12 months to Sep 2026.

Sales$6.8B
20172025
Free cash flow$227M
20172025
Each bar is one fiscal year (2017–2025), summed from four published quarters; the latest is highlighted.

What does management say it's aiming for?

DuPont says it aims to empower the world with essential innovations that help people thrive.

“empower the world with the essential innovations to thrive”

DuPont 2025 Sustainability Report

Who is responsible for the plan?

  • Lori D. KochChief Executive Officer

    Lori D. Koch oversees DuPont's global enterprise strategy, operations, and business portfolio. DuPont manufactures and sells specialty materials, purification technologies, and industrial solutions across global markets.

  • Jeroen BloemhardPresident, Healthcare & Water Technologies

    Jeroen Bloemhard oversees the Healthcare & Water Technologies business segment, managing operations across medical packaging, biopharma components, and water filtration solutions. This business segment generates revenue by providing specialized materials for medical devices and advanced membrane systems for water purification and desalination.

Roles checked November 14, 2026.

What management says it is working on now:

  • Grow healthcare and water businesses

    Management points to growth in medical packaging, biopharma, and industrial and municipal water markets as drivers of recent performance.

    DuPont Reports Second Quarter 2026 Results
  • Improve productivity and margins

    Management says productivity and disciplined execution support margin expansion and the company’s goal of sustainable, profitable growth.

    DuPont Reports Second Quarter 2026 Results
  • Complete the Aramids sale

    DuPont has agreed to sell its Aramids business, subject to customary closing conditions and regulatory approvals.

    DuPont 2025 Form 10-K
  • Streamline operations

    The company is carrying out restructuring intended to simplify and optimize parts of its organization; it expected the program to finish in 2026.

    DuPont 2025 Form 10-K
Organic sales growth, 2026
Slightly above 4%
DuPont Reports Second Quarter 2026 Results
Operating EBITDA, 2026
Approximately $1.76 billion
DuPont Reports Second Quarter 2026 Results
Adjusted earnings per share, 2026
Approximately $7.24
DuPont Reports Second Quarter 2026 Results
Goals in management's own numbers. A target is a promise, not a result.

What's changing right now?

Growth is holding steady. In Q3 2026 it sold 4% more than a year earlier. The year before, quarters averaged 3%.

Since Oct 2026 the share price has risen 7%, from $140.58 to $149.99.

Bull $121.26Base $85.12Bear $45.80Oct 30Nov 16 · $149.99
Daily closing prices we have recorded, set against our bear-to-bull range. Our price records start October 30, 2026.

Recently

Coming up

Our own estimate moved too: the base case went from $51.53 to $85.12 a share between our last two valuations. The biggest reason: Quarterly capital expenditures, continuing operations moved from an unreported prior value to $71.0M, as reported in DuPont Q3 2026 Form 10-Q Condensed Statement of Cash Flows.

What could go wrong?

No business is a sure thing. These are the risks we found, starting with the ones the company itself names. Where a risk would change part of the valuation, it says which.

  1. Environmental claims and shared legacy costs

    PFAS-related claims, cleanup costs and other liabilities from past businesses could exceed current estimates. DuPont also depends on other companies to meet some indemnity and cost-sharing obligations.

    From the company's own filingsWould hit how much of each sale it keepsDuPont 2025 Form 10-K

  2. Aramids sale uncertainty

    The sale’s timing and completion depend on regulatory approvals and other closing conditions. Delays or changes could affect DuPont’s business and financial results.

    From the company's own filingsWould hit how fast sales growDuPont 2025 Form 10-K

  3. Competition

    DuPont competes with large international and regional companies on product innovation, technology, pricing, service and sustainability. Losing ground could weigh on sales.

    From the company's own filingsWould hit how fast sales growDuPont 2025 Form 10-K

  4. Supply and input costs

    Disruptions or higher prices for raw materials and energy could raise costs or make it harder to meet customer demand. Passing those increases on through higher prices depends on market conditions.

    From the company's own filingsWould hit how much of each sale it keepsDuPont 2025 Form 10-K

  5. Restructuring and portfolio changes

    DuPont may not achieve the expected savings or growth from restructuring, acquisitions and business sales. Changes to the business could also leave costs that are difficult to remove.

    From the company's own filingsWould hit how much of each sale it keepsDuPont 2025 Form 10-K

  6. Cybersecurity and system disruptions

    A cyberattack or failure of company or supplier technology systems could disrupt operations, expose confidential information, or lead to legal costs and lost sales.

    From the company's own filingsWould hit how fast sales growDuPont 2025 Form 10-K

  7. Geopolitical disruption in Middle East water projects and regional construction volatility periodically constrain quarterly volumes.

    From our researchWould hit how fast sales growDuPont Q3 2026 Earnings Call Transcript

Is it a good business?

From 2017 to 2025 it earned between -6% and 24% on its shareholders' equity, a median of 3%.

derived computed from the filingsassumption cost of capital from the latest valuation
Return on equity-6%
20172025
Return on invested capital is operating profit after tax (at the median effective rate, 24%) over debt plus equity less cash at each fiscal year end. Return on equity is net income over equity. Both are computed from published quarters.

It bought back shares: the count fell 3.5% in a year, so each remaining share owns a slightly bigger slice.

It owes $1.4B more than it holds in cash. An operating-profit comparison is unavailable from the published quarters.

What might it be worth?

The Valuation snapshot at the top of this page shows the answer. This is how we got there. A share is a slice of the business, so what a share is worth depends on what the business can earn for its owners from here on. We estimate that three ways, from cautious to hopeful, and call the result .

Today a share costs $149.99. Our put its value between $45.80 and $121.26, with $85.12 in the middle. Underneath sit two simpler checks: what it would cost to rebuild the business, its , and what today's profit is worth with no growth at all, its .

Bear case, $45.80

This scenario assumes the business experiences prolonged softness in construction and automotive markets, causing annual sales growth to stall around one percent while higher manufacturing expenses cut into overall profitability.

Base case, $85.12

This scenario assumes the company continues its current trajectory of four percent sales gains led by medical packaging and water purification, while disciplined plant spending preserves strong conversion of earnings into cash.

Bull case, $121.26

This scenario assumes sales growth accelerates toward six percent per year as demand surges for sterile healthcare packaging and industrial water reuse systems, while operational efficiencies expand profit margins.

Another way in: instead of asking what the business is worth, ask what today's price assumes it will do.

Why the gap?

The price expects far more than we do.Price above value: 76%

For DuPont de Nemours to be worth today's $149.99, sales would need to grow about 16.4% a year. We assume 3.8%. Over the last 5 years, sales shrank 11.6% a year.

−20%−10%0%+10%+20%Past 5 yrs −11.6%We assume 3.8%Price needs 16.4%

Or, if sales grow 3.8% as we assume, the price works with a profit margin of 27.7% (we assume 16.5%).

Keep in mind: investors are likely paying for things this model leaves out, such as new businesses or many more years of fast growth.

Do you think sales can grow 16.4% a year?

Try your own numbers

We're moderately sure of this range: it scores 62 out of 100 on our checks. The weakest point is terminal-value dependency.

Test the assumptions

Our base value of $85.12 rests on three assumptions. Change any of them to see how the value per share responds.

  • Revenue growth, 5-year average3.8%
  • Operating margin16.5%
  • Long-term growth rate2.5%

This is an educational explanation built from public filings and our own research, not investment advice. It does not tell you whether to buy or sell anything.

Base estimate

$85.12 -43.2%

Build